University of Novi Sad, Faculty of Medicine, Department of Internal Medicine, Novi Sad + University Clinical Center of Vojvodina, Clinic of Hematology, Novi Sad
Auto-generated profile, based on publicly available information
Marina Dokic
University of Novi Sad, Faculty of Medicine, Department of Internal Medicine, Novi Sad + University Clinical Center of Vojvodina, Clinic of Hematology, Novi Sad
Introduction. Hairy cell leukemia is a rare, indolent chronic lymphoproliferative disorder characterized by circulating B cells with cytoplasmic projections, pancytopenia, and recurrent infections. This study aims to evaluate the efficacy and safety of cladribine in managing the disease among patients treated at the Clinical Centre of Vojvodina. Material and Methods. This study included 34 patients with immunohistochemically confirmed hairy cell leukemia, treated with cladribine from September 2013 to December 2023. Clinical data were reviewed and analyzed using standard statistical methods. Results. At the time of cladribine administration, the median age was 53; 50% of patients were symptomatic, 65% had pancytopenia, and 62% presented with splenomegaly. After the first cycle, 68.75% of patients achieved a complete hematologic response, and the overall response rate was 100%. The median follow-up period was 51 months. During this period, two patients were diagnosed with non-melanoma skin cancers, one with renal cell carcinoma, and one with both myelodysplastic syndrome and prostate cancer. Additionally, 88% of patients experienced at least one infection, with viral infections being the most frequent complications. Four patients died during the follow-up period, and the 5-year survival rate was 97%. Conclusion. Cladribine is an effective treatment for hairy cell leukemia, demonstrating a good safety profile and potential for long-term remission.
Introduction. Acute myeloid leukemia and chronic myeloid leukemia are malignant blood cell disorders characterized by increased angiogenesis. This study aimed to evaluate blood vessel density in bone marrow tissue of patients with acute and chronic myeloid leukemia and to determine whether there is a statistically significant difference compared to a control group. Material and Methods. This retrospective study included 90 bone marrow biopsy samples, categorized into three groups: control, acute myeloid leukemia, and chronic myeloid leukemia. Pathohistological diagnoses were retrieved from the records of the Center for Pathology and Histology of the Clinical Center of Vojvodina. Samples were processed using standard histological and immunohistochemical techniques, examined microscopically, and photographed. Blood vessel density was quantified using ImageJ program, analyzing five microphotographs per sample, with results expressed as percentages. The mean value was calculated for each subject. Data were analyzed statistically and presented numerically, graphically, and in tables. Results. The mean blood vessel density was 1.85% (?}0.56%) in the control group, 3.72 (?}1.67%) in the acute myeloid leukemia group, and 5.42% (?}2.28%) in the chronic myeloid leukemia group. A statistically significant difference in blood vessel density was observed among the groups. Conclusion. The statistically significant difference in blood vessel density between the groups underscores the role of angiogenesis in the pathogenesis of these malignancies and suggests its potential relevance in diagnosis and therapeutic strategies.